Stephenson, Anne

Published purpose

This Priority Announcement (PA) is led by the Institute of Circulatory and Respiratory Health (CIHR-ICRH), in partnership with Cystic Fibrosis Canada. The CIHR-ICRH has the broad mandate of supporting research on the heart, lung, brain (stroke), blood, blood vessels, critical and intensive care, and sleep. Cystic Fibrosis Canada has the mandate to act boldly for all Canadians living with cystic fibrosis so they can live longer, healthier, fuller lives. This PA is focused the management of cystic fibrosis (CF) across the lifespan, including, but not limited to, data acquisition. • The proposed research should inform the management of cystic fibrosis. • The proposed research should consider and/or include more than one (1) developmental or intergenerational period over the lifespan. Examples include, but are not limited to: o one developmental period such as before and after puberty or before and after age 18, or o different developmental periods across generations (e.g. biological parent and fetus or offspring), or o two (2) developmental periods in females related to puberty, child-bearing age and menopause. For the purpose of this PA: • Only research on the management of CF related symptoms and conditions which also fall into ICRH’s mandate will be considered. Examples of eligible projects include, but are not limited to: • Understanding the changing health issues of individuals with CF as they age • Understanding the long-term effects of medications (including CF transmembrane conductance regulators (CFTR) modulators) in CF over the lifespan • Understanding the impact of modulators on fetal development and early childhood • Understanding changes in treatments as people with CF age • Strategies to maintain and enhance lung health over the lifespan • Transitions from pediatric to adult CF care • Preventative strategies for cardiovascular and other complications